Yoshioka W, Noguchi S, Mori-Yoshimura M, Nishino I. Advances in understanding of the natural history, mechanism, extra-muscular manifestations and treatment of GNE myopathy. Neurol Clin Neurosci. 2022;10:289–97.
Nonaka I, Sunohara N, Ishiura S, Satoyoshi E. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. J Neurol Sci. 1981;51:141–55.
Argov Z, Yarom R. Rimmed vacuole myopathy” sparing the quadriceps. J Neurol Sci. 1984;64:33–43.
Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet. 2001;29:83–7.
Nishino I, Noguchi S, Murayama K, Driss A, Sugie K, Oya Y, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology. 2002;59:1689–93.
Nonaka I, Noguchi S, Nishino I. Distal myopathy with rimmed vacuoles and hereditary inclusion body myopathy. Curr Neurol Neurosci Rep. 2005;5:61–5.
Huizing M, Carrillo-Carrasco N, Malicdan MC, Noguchi S, Gahl WA, Mitrani-Rosenbaum S, et al. GNE myopathy: new name and new mutation nomenclature. Neuromuscul Disord. 2014;24:387–9.
Derksen A, Thompson R, Shaikh M, Spendiff S, Perkins TJ, Lochmüller H. Estimating the prevalence of GNE myopathy using population genetic databases. Hum Mutat. 2024;2024:7377504.
Nishino I, Carrillo-Carrasco N, Argov Z. GNE myopathy: current update and future therapy. J Neurol Neurosurg Psychiatry. 2015;86:385–92.
Malicdan MC, Noguchi S, Hayashi YK, Nonaka I, Nishino I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med. 2009;15:690–5.
Yonekawa T, Malicdan MC, Cho A, Hayashi YK, Nonaka I, Mine T, et al. Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice. Brain. 2014;137:2670–9.
Yoshioka W, Nishino I, Noguchi S. Recent advances in establishing a cure for GNE myopathy. Curr Opin Neurol. 2022;35:629–36.
Carrillo N, Malicdan MC, Leoyklang P, Shrader JA, Joe G, Slota C, et al. Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. Genet Med. 2021;23:2067–75.
Park Y-E, Park E, Choi J, Go H, Park DB, Kim MY, et al. Pharmacokinetics and clinical efficacy of 6’-sialyllactose in patients with GNE myopathy: randomized pilot trial. Biomed Pharmacother. 2023;168:115689.
Cho A, Christine M, Malicdan V, Miyakawa M, Nonaka I, Nishino I, et al. Sialic acid deficiency is associated with oxidative stress leading to muscle atrophy and weakness in GNE myopathy. Hum Mol Genet. 2017;26:3081–93.
Mitrani-Rosenbaum S, Yakovlev L, Becker Cohen M, Telem M, Elbaz M, Yanay N, et al. Sustained expression and safety of human GNE in normal mice after gene transfer based on AAV8 systemic delivery. Neuromuscul Disord. 2012;22:1015–24.
Crowe KE, Zygmunt DA, Heller K, Rodino-Klapac L, Noguchi S, Nishino I, et al. Visualizing muscle sialic acid expression in the GNED207VTgGne-/- Cmah-/- model of GNE myopathy: a comparison of dietary and gene therapy approaches. J Neuromuscul Dis. 2022;9:53–71.
Celeste FV, Vilboux T, Ciccone C, de Dios JK, Malicdan MC, Leoyklang P, et al. Mutation update for GNE gene variants associated with GNE myopathy. Hum Mutat. 2014;35:915–26.
Cho A, Hayashi YK, Monma K, Oya Y, Noguchi S, Nonaka I, et al. Mutation profile of the GNE gene in Japanese patients with distal myopathy with rimmed vacuoles (GNE myopathy). J Neurol Neurosurg Psychiatry. 2014;85:914–7.
Leroy JG, Seppala R, Huizing M, Dacremont G, De Simpel H, Van Coster RN, et al. Dominant inheritance of sialuria, an inborn error of feedback inhibition. Am J Hum Genet. 2001;68:1419–27.
Zhu W, Mitsuhashi S, Yonekawa T, Noguchi S, Huei JC, Nalini A, et al. Missing genetic variations in GNE myopathy: rearrangement hotspots encompassing 5’UTR and founder allele. J Hum Genet. 2017;62:159–66.
Garland J, Stephen J, Class B, Gruber A, Ciccone C, Poliak A, et al. Identification of an Alu element-mediated deletion in the promoter region of GNE in siblings with GNE myopathy. Mol Genet Genom Med. 2017;5:410–7.
Chakravorty S, Berger K, Arafat D, Nallamilli B, Subramanian HP, Joseph S, et al. Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter deletion. Muscle Nerve. 2019;60:98–103.
Xing Y, Zhao L, Zhao R, Liu Q, Wang J, Wang L, et al. Analysis of the pathogenicity of novel GNE mutations and clinical, pathological, and genetic characteristics of GNE myopathy in Chinese population. Orphanet J Rare Dis. 2025;20:161.
Jiao K, Zhang J, Li Q, Lv X, Yu Y, Zhu B, et al. Novel variants and genotype-phenotype correlation in a multicentre cohort of GNE myopathy in China. J Med Genet. 2024;61:1053–61.
Schwarzkopf M, Knobeloch K-P, Rohde E, Hinderlich S, Wiechens N, Lucka L, et al. Sialylation is essential for early development in mice. Proc Natl Acad Sci USA. 2002;99:5267–70.
Carrillo N, Malicdan MC, Huizing M. GNE myopathy: etiology, diagnosis, and therapeutic challenges. Neurotherapeutics. 2018;15:900–14.
Yoshioka W, Iida A, Sonehara K, Yamamoto K, Oya Y, Mori-Yoshimura M, et al. Multidimensional analyses of the pathomechanism caused by the non-catalytic GNE variant, c.620A>T, in patients with GNE myopathy. Sci Rep. 2022;12:21806.
Sim JE, Park H-J, Shin HY, Nam TS, Kim SM, Choi YC. Clinical characteristics and molecular genetic analysis of Korean patients with GNE myopathy. Yonsei Med J. 2013;54:578–82.
Chamova T, Guergueltcheva V, Gospodinova M, Krause S, Cirak S, Kaprelyan A, et al. GNE myopathy in Roma patients homozygous for the p.I618T founder mutation. Neuromuscul Disord. 2015;25:713–8.
Pogoryelova O, Cammish P, Mansbach H, Argov Z, Nishino I, Skrinar A, et al. Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: first report from the GNE myopathy Disease Monitoring Program, registry portion. Neuromuscul Disord. 2018;28:158–68.
Baskar D, Reddy N, Preethish-Kumar V, Polavarapu K, Nishadham V, Vengalil S, et al. GNE myopathy: genotype-phenotype correlation and disease progression in an Indian cohort. J Neuromuscul Dis. 2024;11:959–68.
Yoshioka W, Nakamura H, Oba M, Saito Y, Nishino I, Mori-Yoshimura M, et al. Large phenotypic diversity by genotype in patients with GNE myopathy: 10 years after the establishment of a national registry in Japan. J Neurol. Published Online First: 1 May 2024. https://doi.org/10.1007/s00415-024-12396-z.
Bhattacharya S, Khadilkar SV, Nalini A, Ganapathy A, Mannan AU, Majumder PP, et al. Mutation spectrum of GNE myopathy in the Indian sub-continent. J Neuromuscul Dis. 2018;5:85–92.
Fatehi F, Advani S, Okhovat AA, Ziaadini B, Shamshiri H, Nafissi S. Thigh and leg muscle MRI findings in GNE myopathy. J Neuromuscul Dis. 2021;8:735–42.
Yoshioka W, Miyasaka N, Okubo R, Shimizu R, Takahashi Y, Oda Y, et al. Pregnancy in GNE myopathy patients: a nationwide repository survey in Japan. Orphanet J Rare Dis. 2020;15:245.
Yoshioka W, Shimizu R, Takahashi Y, Oda Y, Yoshida S, Ishihara N, et al. Extra-muscular manifestations in GNE myopathy patients: a nationwide repository questionnaire survey in Japan. Clin Neurol Neurosurg. 2022;212:107057.
Mori-Yoshimura M, Yajima H, Oya Y, Mizuno K, Noguchi S, Nishino I, et al. Long-term evaluation parameters in GNE myopathy: a 5-year observational follow-up natural history study. BMJ Neurol Open. 2022;4:e000362.
Sparks S, Rakocevic G, Joe G, Manoli I, Shrader J, Harris-Love M, et al. Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurol. 2007;7:3.
Suzuki N, Mori-Yoshimura M, Katsuno M, Takahashi MP, Yamashita S, Oya Y, et al. Safety and efficacy of aceneuramic acid in GNE myopathy: open-label extension study. J Neurol Neurosurg Psychiatry. 2024;95:1093–94.
Kakkis E, Maurer M, Shah P, Donikyan M, Ahmed R. T.P.13 A phase 1 safety and pharmacokinetic study of sialic acid-extended release tablets in patients with Hereditary Inclusion Body Myopathy (HIBM or GNE myopathy). Neuromuscul Disord. 2012;22:850.
Argov Z, Caraco Y, Lau H, Pestronk A, Shieh PB, Skrinar A, et al. Aceneuramic acid extended release administration maintains upper limb muscle strength in a 48-week study of subjects with GNE myopathy: Results from a Phase 2, randomized, controlled study. J Neuromuscul Dis. 2016;3:49–66.
Lochmüller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, et al. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology. 2019;92:e2109–17.
Suzuki N, Mori-Yoshimura M, Katsuno M, Takahashi MP, Yamashita S, Oya Y, et al. Phase II/III study of aceneuramic acid administration for GNE myopathy in Japan. J Neuromuscul Dis. 2023;10:555–66.
Mori-Yoshimura M, Suzuki N, Katsuno M, Takahashi MP, Yamashita S, Oya Y, et al. Efficacy confirmation study of aceneuramic acid administration for GNE myopathy in Japan. Orphanet J Rare Dis. 2023;18:241.
Bardor M, Nguyen DH, Diaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem. 2005;280:4228–37.
Xu X, Wang AQ, Latham LL, Celeste F, Ciccone C, Malicdan MC, et al. Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy. Mol Genet Metab. 2017;122:126–34.
Van Wart S, Mager DE, Bednasz CJ, Huizing M, Carrillo N. Population pharmacokinetic model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in subjects with GNE myopathy. Drugs R D. 2021;21:189–202.
Nöhle U, Schauer R. Uptake, metabolism and excretion of orally and intravenously administered, 14C- and 3H-labeled N-acetylneuraminic acid mixture in the mouse and rat. Hoppe Seylers Z Physiol Chem. 1981;362:1495–506.
Park Y-E, Choi J, Kim L, Park E, Go H, Shin J. A pilot trial for efficacy confirmation of 6’-sialyllactose supplementation in GNE myopathy: randomized, placebo-controlled trial. Mol Genet Metab. 2025;144:108614.
Nemunaitis G, Jay CM, Maples PB, Gahl WA, Huizing M, Yardeni T, et al. Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther. 2011;22:1331–41.
Tal-Goldberg T, Lorain S, Mitrani-Rosenbaum S. Correction of the Middle Eastern M712T mutation causing GNE myopathy by trans-splicing. Neuromolecular Med. 2014;16:322–31.
Zygmunt DA, Crowe KE, Flanigan KM, Martin PT. Comparison of serum rAAV serotype-specific antibodies in patients with Duchenne muscular dystrophy, Becker muscular dystrophy, inclusion body myositis, or GNE myopathy. Hum Gene Ther. 2017;28:737–46.
Berns KI, Muzyczka N. AAV: an overview of unanswered questions. Hum Gene Ther. 2017;28:308–13.
Khademian H, Mehravar E, Urtizberea J, Sagoo S, Sandoval L, Carbajo R, et al. Prevalence of GNE p.M712T and hereditary inclusion body myopathy (HIBM) in Sangesar population of Northern Iran: Prevalence ofGNEp.M712T and HIBM. Clin Genet. 2013;84:589–92.
Tilemis FN, Marinakis NM, Veltra D, Svingou M, Kekou K, Mitrakos A, et al. Germline CNV detection through whole-Exome Sequencing (WES) data analysis enhances resolution of rare genetic diseases. Gene. 2023;14. https://doi.org/10.3390/genes14071490.
Miao J, Wei X-J, Wang X, Yin X, Yu XF. A case report: identification of a novel exon 1 deletion mutation in the GNE gene in a Chinese patient with GNE myopathy. Medicine. 2020;99:e22663.
Chen Y, Xi J, Zhu W, Lin J, Luo S, Yue D, et al. GNE myopathy in Chinese population: hotspot and novel mutations. J Hum Genet. 2019;64:11–6.
Del Bo R, Baron P, Prelle A, Serafini M, Moggio M, Fonzo AD, et al. Novel missense mutation and large deletion of GNE gene in autosomal-recessive inclusion-body myopathy. Muscle Nerve. 2003;28:113–7.
Murtazina A, Nikitin S, Rudenskaya G, Sharkova I, Borovikov A, Sparber P, et al. Genetic and clinical spectrum of GNE myopathy in Russia. Genes. 2022;13:1991.